Morgan Stanley set a €70.00 ($81.40) target price on Fresenius Medical Care AG & Co. KGaA (ETR:FME) in a research note issued to investors on Wednesday morning, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.
Several other research analysts have also weighed in on FME. HSBC set a €101.00 ($117.44) target price on Grenke and gave the stock a buy rating in a report on Thursday, April 25th. UBS Group lifted their target price on LyondellBasell Industries from $86.00 to $89.00 and gave the stock a neutral rating in a report on Thursday, July 11th. Barclays reiterated a hold rating and set a $14.00 target price on shares of MACOM Technology Solutions in a report on Thursday, June 20th. JPMorgan Chase & Co. reiterated a neutral rating on shares of SUZUKI MTR CORP/ADR in a report on Wednesday. Finally, Independent Research set a €74.00 ($86.05) target price on Fresenius Medical Care AG & Co. KGaA and gave the stock a neutral rating in a report on Monday, June 17th. Seven analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of €82.57 ($96.01).
FME stock opened at €67.00 ($77.91) on Wednesday. The business’s 50-day simple moving average is €68.38. The company has a current ratio of 1.02, a quick ratio of 0.67 and a debt-to-equity ratio of 100.05. The company has a market capitalization of $20.45 billion and a price-to-earnings ratio of 10.43. Fresenius Medical Care AG & Co. KGaA has a 1-year low of €55.44 ($64.47) and a 1-year high of €91.74 ($106.67).
Fresenius Medical Care AG & Co KGaA, a kidney dialysis company, provides dialysis care and related services, and other health care services in Germany, the United States, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.
Featured Article: Does a trade war provide a risk to the global economy?
Receive News & Ratings for Fresenius Medical Care AG & Co. KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. KGaA and related companies with MarketBeat.com's FREE daily email newsletter.